Treatments for cancers of unknown primary origin

In the vast majority of cases, treatment for cancer of unknown primary is based on systemic drug therapy aimed at treating all metastatic sites. This treatment is most often administered intravenously following the placement of a dedicated vascular access device (implantable port or central venous catheter). Its primary goal is to control disease progression. Treatment duration varies widely depending on treatment effectiveness and side effects.

Several types of medications may be used, depending on disease characteristics and the results of pathological and molecular analyses. When there is no indication of a likely tissue of origin or an identifiable therapeutic target, first-line treatment typically consists of broad-spectrum chemotherapy. More specific chemotherapy regimens may be proposed when there is strong suspicion that the metastases originate from a particular tissue.

Immunotherapy may be used alone or in combination with chemotherapy when cancer cells display specific features. In some cases, targeted therapies directed against specific genetic alterations may also be offered.

Local treatments such as radiotherapy or surgery may be proposed, particularly when the number of metastases is limited. These local treatments are most often combined with systemic therapy.
 

More information about treatments at Institut Curie

In addition to anticancer treatment, management of disease-related symptoms is essential. Depending on individual needs, supportive care may be provided to relieve pain, improve nutritional status, or reduce fatigue.

More information about supportive care